Litcius/Paper detail

Novel nomogram developed for determining suitability of metastatic castration-resistant prostate cancer patients to receive maximum benefit from radium-223 dichloride treatment—Japanese Ra-223 Therapy in Prostate Cancer using Bone Scan Index (J-RAP-BSI) Trial

Kazuhiro Kitajima, Masataka Igeta, Junpei Kuyama, Takashi Kawahara, Tsuyoshi Suga, Tomoaki Otani, Shigeyasu Sugawara, Yumiko Kono, Yukihisa Tamaki, Ayumi Seko‐Nitta, Yoshinobu Ishiwata, Kimiteru Ito, Akira Toriihara, Shirô Watanabe, Makoto Hosono, Hideaki Miyake, Shingo Yamamoto, Mitsuhiro Narita, Takashi Daimon, Koichiro Yamakado

2022European Journal of Nuclear Medicine and Molecular Imaging19 citationsDOI

Topics & Concepts

MedicineProstate cancerNomogramOncologyInternal medicineRadium-223Hazard ratioBone scintigraphyUrologyEnzalutamideAndrogen deprivation therapyProstate-specific antigenBone metastasisCancerNuclear medicineConfidence intervalAndrogen receptorProstate Cancer Treatment and ResearchProstate Cancer Diagnosis and TreatmentBone health and treatments
Novel nomogram developed for determining suitability of metastatic castration-resistant prostate cancer patients to receive maximum benefit from radium-223 dichloride treatment—Japanese Ra-223 Therapy in Prostate Cancer using Bone Scan Index (J-RAP-BSI) Trial | Litcius